Melanoma skin cancer develops in the melanocyte cells of the skin. Although melanoma
skin cancer can start in other parts of the body where melanocytes are found, these types of …

Aims To make recommendations on managing the surveillance of patients with stage I, II, III
or resectable IV melanoma who are clinically free of disease following treatment with …

Purpose Appropriate surveillance of patients with melanoma treated with curative intent is
vital to improve patient outcomes. A systematic review was conducted to capture …

The incidence of melanoma has been rising over the past 20 years; however, the number of
deaths attributed to melanoma has remained unchanged (1). Over 76,000 new melanoma …

Vale L, Kunonga P, Coughlan D, et al. Optimal surveillance strategies for patients with stage
1 cutaneous melanoma post primary tumour excision: three systematic reviews and an …

Methods This review adheres to the guidelines for the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement to ensure transparency of the …

e21570 Background: Advancements in systemic therapy have reduced recurrence, and the
adoption of nodal surveillance in place of dissection has reduced morbidity for patients with …

Introduction: There are a lack of established guidelines for the surveillance of high-risk
cutaneous melanoma patients following initial therapy. We describe a novel approach to the …

INTRODUCTION—Cutaneous melanoma has the potential to metastasize to any organ,
including the skin, lymph nodes, subcutaneous tissues, lungs, liver, bone, brain, and visceral …

Background After appropriate initial therapy for patients with stage II-III melanoma, there is
no consensus regarding surveillance. Thus, follow-up is highly variable among institutions …